Precision BioSciences (DTIL) AI Stock Analysis

• Market Cap: $86.75M
• Dividend Yield: N/A
• Average Volume (3M): 123.92K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.09
• Revenue Growth: -98.56%
• EPS Growth: -347.81%
• Country: US
• Employees: 108
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -2.13
• Shares Outstanding: 11,786,991
• 10 Day Avg. Volume: 185,671
• 30 Day Avg. Volume: 123,923
• PEG Ratio: -0.03
• Price to Book (P/B): 0.46
• Price to Sales (P/S): 0.38
• P/FCF Ratio: -0.44
• Enterprise Value/Market Cap: 0.16
• Enterprise Value/Revenue: 19.48
• Enterprise Value/Gross Profit: -1.24K
• Enterprise Value/Ebitda: -0.17
• 1Y Price Target: $36.33
• Price Target Upside: 393.61% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 53 Neutral
• Price Target: $7.50 ▲(1.90% Upside)

The overall stock score is primarily impacted by the company's weak financial performance, with significant revenue decline and profitability issues. Despite this, the stock shows strong technical momentum, which provides some positive outlook. However, the negative valuation metrics, including a negative P/E ratio, weigh down the overall score.

Positive Factors

Gene Editing Pipeline Progress

The progress in the gene editing pipeline, including promising Phase 1 data for PBGENE-HBV, indicates potential for future therapeutic breakthroughs and revenue growth.

Strategic Collaborations

Strategic collaborations provide a sustainable revenue stream through upfront payments, research funding, and potential royalties, supporting long-term growth.

ARCUS Technology

ARCUS technology offers a competitive advantage in gene editing, enabling precise DNA edits and fostering innovation in genetic therapies.

Negative Factors

Revenue Decline

Significant revenue decline poses a challenge to financial stability and growth, necessitating strategic adjustments to reverse the trend.

Profitability Challenges

Ongoing profitability issues, indicated by negative margins, threaten long-term financial health and require operational improvements.

Cash Flow Issues

Cash flow challenges limit financial flexibility and may hinder investment in growth initiatives, impacting future business prospects.

Precision BioSciences Business Overview & Revenue Model

Company Description

Precision BioSciences, Inc. (DTIL) is a biotechnology company that specializes in gene editing and genetic therapies. The company operates primarily in the life sciences sector, focusing on developing innovative solutions for various diseases, including cancer and genetic disorders. Precision BioSciences utilizes its proprietary ARCUS technology, a genome editing platform designed to create precise and efficient edits in DNA, enabling the development of therapies that can potentially transform treatment paradigms. The company collaborates with academic institutions and biopharmaceutical companies to advance its research and therapeutic candidates.

How the Company Makes Money

Precision BioSciences generates revenue through a combination of partnerships, collaborations, and licensing agreements. The company often enters into strategic alliances with pharmaceutical companies to co-develop therapies, which can provide upfront payments, research funding, and milestone payments as specific development goals are achieved. Additionally, Precision BioSciences may receive royalties on future product sales resulting from these collaborations. The company also pursues grant funding and may generate revenue from its proprietary technology through licensing deals, allowing others to utilize its ARCUS genome editing platform in their own research and development efforts.

Precision BioSciences Financial Statement Overview

Summary

Precision BioSciences faces significant financial challenges, particularly in terms of revenue decline and profitability. While the balance sheet shows low leverage, the negative return on equity and cash flow issues highlight ongoing financial instability. The company needs to address its revenue and profitability issues to improve its financial health.

Income Statement

Precision BioSciences has experienced a significant decline in revenue, with a TTM revenue growth rate of -97.53%. The company also shows negative net profit and EBIT margins, indicating ongoing profitability challenges. Despite a high gross profit margin, the overall financial health of the income statement is weak due to substantial losses.

Balance Sheet

The company's balance sheet shows a relatively low debt-to-equity ratio of 0.041 in the TTM period, suggesting manageable leverage. However, the return on equity is negative, reflecting poor profitability. The equity ratio is not provided, but the overall balance sheet stability is moderate given the low leverage.

Cash Flow

The cash flow statement reveals a negative operating cash flow and free cash flow, with a slight improvement in free cash flow growth. The operating cash flow to net income ratio is negative, indicating cash flow challenges. The free cash flow to net income ratio is slightly above 1, suggesting some alignment between cash flow and reported earnings.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	698.00K	68.70M	48.73M	25.10M	115.53M	24.29M
Gross Profit	-11.00K	68.70M	40.47M	16.09M	115.53M	24.29M
EBITDA	-80.34M	13.53M	-32.04M	-62.79M	-20.27M	-99.19M
Net Income	-83.60M	7.17M	-61.32M	-122.91M	-30.92M	-109.01M
Balance Sheet
Total Assets	93.51M	136.39M	159.78M	238.17M	211.50M	150.16M
Cash, Cash Equivalents and Short-Term Investments	44.87M	86.31M	116.68M	189.58M	143.66M	89.80M
Total Debt	1.46M	30.05M	31.27M	27.04M	9.11M	10.52M
Total Liabilities	76.88M	80.00M	140.92M	177.74M	120.33M	105.73M
Stockholders Equity	16.63M	56.39M	18.86M	60.43M	91.17M	44.42M
Cash Flow
Free Cash Flow	-73.42M	-58.70M	-86.39M	-49.07M	-16.66M	-92.42M
Operating Cash Flow	-73.28M	-58.45M	-84.11M	-45.75M	-10.85M	-87.39M
Investing Cash Flow	-406.00K	-215.00K	5.83M	-3.32M	-5.80M	-5.03M
Financing Cash Flow	23.57M	50.45M	5.39M	94.98M	70.52M	1.33M

Precision BioSciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7.36
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DTIL, the sentiment is Positive. The current price of 7.36 is above the 20-day moving average (MA) of 6.85, above the 50-day MA of 5.76, and above the 200-day MA of 5.13, indicating a bullish trend. The MACD of 0.70 indicates Negative momentum. The RSI at 58.35 is Neutral, neither overbought nor oversold. The STOCH value of 68.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DTIL.

Precision BioSciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTMX	―	$648.11M	6.87	108.21%	―	18.01%	306.76%
DTIL	―	$86.75M	-0.83	-143.89%	―	-98.56%	-347.81%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BLUE	―	―	―	―	―	127.51%	56.94%
IMA	―	$84.31M	―	-23.76%	―	-100.00%	55.32%
ACRV	―	$62.60M	―	-47.87%	―	―	18.86%
ACET	―	$111.88M	-0.56	-64.39%	―	―	48.45%

Precision BioSciences Corporate Events

Precision BioSciences Advances with Promising Hepatitis B Gene-Editing Study

Precision BioSciences is conducting a Phase 1 study titled ‘A Phase 1, Open-Label, First-in-Human, Dose Escalation (Part 1) and Expansion (Part 2) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of PBGENE-HBV in Participants With Chronic Hepatitis B (ELIMINATE-B).’ The study aims to assess the safety, tolerability, pharmacokinetics, and antiviral activity of PBGENE-HBV, a novel gene-editing intervention for chronic hepatitis B.

Precision BioSciences Updates Executive Employment Agreements

On August 26, 2025, Precision BioSciences amended and restated employment agreements for its key executives to retain them and reflect updated compensation terms. These agreements include provisions for termination without cause and require funding of severance and expenses in an escrow account, with interest and unused funds benefiting the company.

The most recent analyst rating on (DTIL) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Precision BioSciences stock, see the DTIL Stock Forecast page.

Precision BioSciences Reports Significant Quarterly Loss

Precision BioSciences, Inc., a biotechnology company specializing in gene editing technologies, focuses on developing in vivo therapies for genetic and infectious diseases using its proprietary ARCUS genome editing platform. In its latest earnings report for the quarter ending June 30, 2025, Precision BioSciences reported a significant net loss of $23.5 million, a notable decline from the $32.7 million net income reported in the same quarter of the previous year. The company’s revenue also saw a sharp decrease, with only $18,000 reported for the quarter compared to $49.9 million in the previous year. This downturn is attributed to the termination of certain agreements and a strategic shift to focus solely on in vivo gene editing therapies. Despite the financial challenges, the company continues to invest in research and development, with expenses totaling $12.8 million for the quarter. Looking ahead, Precision BioSciences remains committed to advancing its ARCUS platform and exploring new collaborations to support its strategic focus on gene editing therapies.

Precision BioSciences Reports Promising Phase 1 Trial Results

On August 6, 2025, Precision BioSciences announced results from its Phase 1 ELIMINATE-B clinical trial for PBGENE-HBV, a treatment for hepatitis B. The trial’s Cohort 1, which involved three patients receiving low-dose PBGENE-HBV, showed promising safety and efficacy results, with no serious adverse events and significant reductions in hepatitis B surface antigen levels. Cohort 2 is underway, with one patient completing three doses and two others receiving one dose each, showing similar safety profiles. The favorable outcomes have led to the recommendation to initiate Cohort 3, with further updates expected later in 2025.

The most recent analyst rating on (DTIL) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Precision BioSciences stock, see the DTIL Stock Forecast page.